

Maria Vicario Perez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2213683/publications.pdf>

Version: 2024-02-01

64
papers

4,649
citations

108046

37
h-index

129628

63
g-index

65
all docs

65
docs citations

65
times ranked

5220
citing authors

#	ARTICLE	IF	CITATIONS
1	Human milk oligosaccharides alleviate stress-induced visceral hypersensitivity and associated microbiota dysbiosis. <i>Journal of Nutritional Biochemistry</i> , 2022, 99, 108865.	1.9	7
2	Eosinophils in the Gastrointestinal Tract: Key Contributors to Neuro-Immune Crosstalk and Potential Implications in Disorders of Brain-Gut Interaction. <i>Cells</i> , 2022, 11, 1644.	1.8	7
3	Mucosal Plasma Cell Activation and Proximity to Nerve Fibres Are Associated with Glycocalyx Reduction in Diarrhoea-Predominant Irritable Bowel Syndrome: Jejunal Barrier Alterations Underlying Clinical Manifestations. <i>Cells</i> , 2022, 11, 2046.	1.8	4
4	The alternative serotonin transporter promoter P2 impacts gene function in females with irritable bowel syndrome. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 8047-8061.	1.6	5
5	Mometasone furoate and fluticasone furoate are equally effective in restoring nasal epithelial barrier dysfunction in allergic rhinitis. <i>World Allergy Organization Journal</i> , 2021, 14, 100585.	1.6	8
6	Duodenal acidification induces gastric relaxation and alters epithelial barrier function by a mast cell independent mechanism. <i>Scientific Reports</i> , 2020, 10, 17448.	1.6	6
7	Overexpression of corticotropin-releasing factor in intestinal mucosal eosinophils is associated with clinical severity in Diarrhea-Predominant Irritable Bowel Syndrome. <i>Scientific Reports</i> , 2020, 10, 20706.	1.6	21
8	Increased Colonic Epithelial Permeability and Mucosal Eosinophilia in Ulcerative Colitis in Remission Compared With Irritable Bowel Syndrome and Health. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 974-984.	0.9	30
9	Peripheral Corticotropin-Releasing Factor Triggers Jejunal Mast Cell Activation and Abdominal Pain in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2020, 115, 2047-2059.	0.2	16
10	Intestinal Mucosal Mast Cells: Key Modulators of Barrier Function and Homeostasis. <i>Cells</i> , 2019, 8, 135.	1.8	115
11	Maintaining Intestinal Mucosal Integrity by Plugging Leaks with Homoectoine. <i>Digestive Diseases and Sciences</i> , 2019, 64, 292-293.	1.1	2
12	A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies. <i>Advances in Therapy</i> , 2018, 35, 289-310.	1.3	152
13	Decreased TESK1-mediated cofilin 1 phosphorylation in the jejunum of IBS-D patients may explain increased female predisposition to epithelial dysfunction. <i>Scientific Reports</i> , 2018, 8, 2255.	1.6	18
14	Toll-like receptors-mediated pathways activate inflammatory responses in the esophageal mucosa of adult eosinophilic esophagitis. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e147.	1.3	31
15	Activation of Eosinophils and Mast Cells in Functional Dyspepsia: an Ultrastructural Evaluation. <i>Scientific Reports</i> , 2018, 8, 5383.	1.6	58
16	Epithelial immunity: priming defensive responses in the intestinal mucosa. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, G247-G255.	1.6	22
17	Intestinal Barrier Function in Chronic Kidney Disease. <i>Toxins</i> , 2018, 10, 298.	1.5	78
18	miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea. <i>Gut</i> , 2017, 66, 1537.1-1538.	6.1	105

#	ARTICLE	IF	CITATIONS
19	Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 909-922.	1.9	81
20	miR-16 and miR-103 impact 5-HT4 receptor signalling and correlate with symptom profile in irritable bowel syndrome. <i>Scientific Reports</i> , 2017, 7, 14680.	1.6	46
21	Downregulation of mucosal mast cell activation and immune response in diarrhoea-irritable bowel syndrome by oral disodium cromoglycate: A pilot study. <i>United European Gastroenterology Journal</i> , 2017, 5, 887-897.	1.6	40
22	Vasoactive Intestinal Polypeptide and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2017, 153, 948-960.e3.	0.6	98
23	Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 53-63.	1.4	47
24	Abnormal Barrier Function in Gastrointestinal Disorders. <i>Handbook of Experimental Pharmacology</i> , 2016, 239, 193-217.	0.9	43
25	A weakly acidic solution containing deoxycholic acid induces esophageal epithelial apoptosis and impairs integrity in an in vivo perfusion rabbit model. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, G487-G496.	1.6	18
26	The joint power of sex and stress to modulate brain-gut-microbiota axis and intestinal barrier homeostasis: implications for irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2016, 28, 463-486.	1.6	62
27	The role of mast cells in functional GI disorders. <i>Gut</i> , 2016, 65, 155-168.	6.1	251
28	Dietary treatment modulates mast cell phenotype, density, and activity in adult eosinophilic oesophagitis. <i>Clinical and Experimental Allergy</i> , 2016, 46, 78-91.	1.4	39
29	Towards a new paradigm of microscopic colitis: Incomplete and variant forms. <i>World Journal of Gastroenterology</i> , 2016, 22, 8459.	1.4	19
30	194 Eosinophils and Mast Cells in Functional Dyspepsia: Ultrastructural Evaluation of Activation. <i>Gastroenterology</i> , 2015, 148, S-49.	0.6	3
31	Role of Corticotropin-releasing Factor in Gastrointestinal Permeability. <i>Journal of Neurogastroenterology and Motility</i> , 2015, 21, 033-050.	0.8	84
32	144 Jejunal Mucosal Eosinophils Show Higher Corticotropin-Releasing Hormone Content in Association With Clinical Manifestations in Diarrhea-Prone Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2015, 148, S-38.	0.6	2
33	Su1386 Clinical Benefit and Intestinal Mucosal Transcriptome Modulation After Long-Term Mast Cell Stabilization With Oral Disodium Cromoglycate in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Patients. <i>Gastroenterology</i> , 2015, 148, S-494.	0.6	4
34	Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations. <i>Gut</i> , 2015, 64, 1379-1388.	6.1	94
35	The intestinal barrier function and its involvement in digestive disease. <i>Revista Espanola De Enfermedades Digestivas</i> , 2015, 108, 686-96.	0.1	121
36	Intestinal Barrier Function and the Brain-Gut Axis. <i>Advances in Experimental Medicine and Biology</i> , 2014, 817, 73-113.	0.8	43

#	ARTICLE	IF	CITATIONS
37	Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. <i>Gut</i> , 2014, 63, 262-271.	6.1	322
38	Response to Rodrigo et al.. <i>American Journal of Gastroenterology</i> , 2014, 109, 1291-1292.	0.2	1
39	Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. <i>Gut</i> , 2013, 62, 1160-1168.	6.1	229
40	Usefulness and Limitations of Sequential Serum Tryptase for the Diagnosis of Anaphylaxis in 102 Patients. <i>International Archives of Allergy and Immunology</i> , 2013, 160, 192-199.	0.9	144
41	Polymorphisms: genetic variations associated with irritable bowel syndrome. <i>Revista Espanola De Enfermedades Digestivas</i> , 2013, 105, 375-377.	0.1	0
42	The Jejunum of Diarrhea-Predominant Irritable Bowel Syndrome Shows Molecular Alterations in the Tight Junction Signaling Pathway That Are Associated With Mucosal Pathobiology and Clinical Manifestations. <i>American Journal of Gastroenterology</i> , 2012, 107, 736-746.	0.2	169
43	Cellular and Molecular Basis of Intestinal Barrier Dysfunction in the Irritable Bowel Syndrome. <i>Gut and Liver</i> , 2012, 6, 305-315.	1.4	95
44	Chronic psychosocial stress induces reversible mitochondrial damage and corticotropin-releasing factor receptor type-1 upregulation in the rat intestine and IBS-like gut dysfunction. <i>Psychoneuroendocrinology</i> , 2012, 37, 65-77.	1.3	62
45	Acute experimental stress evokes a differential gender-determined increase in human intestinal macromolecular permeability. <i>Neurogastroenterology and Motility</i> , 2012, 24, 740.	1.6	55
46	Eosinophils Express Muscarinic Receptors and Corticotropin-Releasing Factor to Disrupt the Mucosal Barrier in Ulcerative Colitis. <i>Gastroenterology</i> , 2011, 140, 1597-1607.	0.6	68
47	Evaluation of oesophageal mucosa integrity by the intraluminal impedance technique. <i>Gut</i> , 2011, 60, 885-892.	6.1	226
48	Role of microRNA in IBS with increased gut permeability. <i>Gut</i> , 2010, 59, 710-712.	6.1	12
49	Local B cells and IgE production in the oesophageal mucosa in eosinophilic oesophagitis. <i>Gut</i> , 2010, 59, 12-20.	6.1	191
50	Chronological assessment of mast cell-mediated gut dysfunction and mucosal inflammation in a rat model of chronic psychosocial stress. <i>Brain, Behavior, and Immunity</i> , 2010, 24, 1166-1175.	2.0	88
51	Impaired intestinal molecular tightness in the mucosa of irritable bowel syndrome: what are the mediators?. <i>Gut</i> , 2009, 58, 161-162.	6.1	4
52	Metabotyping of Biofluids Reveals Stress-Based Differences in Gut Permeability in Healthy Individuals. <i>Journal of Proteome Research</i> , 2009, 8, 4799-4809.	1.8	33
53	Stress neuropeptides evoke epithelial responses via mast cell activation in the rat colon. <i>Psychoneuroendocrinology</i> , 2008, 33, 1248-1256.	1.3	61
54	Maladaptive Intestinal Epithelial Responses to Life Stress May Predispose Healthy Women to Gut Mucosal Inflammation. <i>Gastroenterology</i> , 2008, 135, 163-172.e1.	0.6	112

#	ARTICLE	IF	CITATIONS
55	Neuropharmacology of Stress-Induced Mucosal Inflammation: Implications for Inflammatory Bowel Disease and Irritable Bowel Syndrome. <i>Current Molecular Medicine</i> , 2008, 8, 258-273.	0.6	28
56	Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. <i>Gut</i> , 2007, 56, 203-209.	6.1	330
57	IL-13 involvement in eosinophilic esophagitis: Transcriptome analysis and reversibility with glucocorticoids. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 1292-1300.	1.5	395
58	Dietary Glutamine Affects Mucosal Functions in Rats with Mild DSS-Induced Colitis. <i>Journal of Nutrition</i> , 2007, 137, 1931-1937.	1.3	62
59	Targeting mast cells in the treatment of functional gastrointestinal disorders. <i>Current Opinion in Pharmacology</i> , 2006, 6, 541-546.	1.7	50
60	Immune cell activation and subsequent epithelial dysfunction by Staphylococcus enterotoxin B is attenuated by the green tea polyphenol (âˆ“)-epigallocatechin gallate. <i>Cellular Immunology</i> , 2005, 237, 7-16.	1.4	45
61	Induction of Colitis in Young Rats by Dextran Sulfate Sodium. <i>Digestive Diseases and Sciences</i> , 2005, 50, 143-150.	1.1	18
62	Dietary Unsaturated Long-Chain Fatty Acids Modify D-Glucose Absorption in Weaning Rats. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2005, 40, 151-156.	0.9	1
63	Induction of colitis in young rats by dextran sulfate sodium. <i>Digestive Diseases and Sciences</i> , 2005, 50, 143-50.	1.1	6
64	Dietary Plasma Protein Affects the Immune Response of Weaned Rats Challenged with S. aureus Superantigen B. <i>Journal of Nutrition</i> , 2004, 134, 2667-2672.	1.3	62